Realtime | Geld | Brief | Zeit |
---|---|---|---|
4,810 | 4,826 | 07:57 | |
4,810 | 4,826 | 07:56 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
H LUNDBECK Aktie jetzt für 0€ handeln | |||||
Di | Lundbeck's Lu AG13909 Secures Orphan Drug Status In US And EU For Rare Adrenal Disorder | 2 | RTTNews | ||
Di | H. Lundbeck A/S: Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia | 158 | PR Newswire | Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disease1 with an estimated global incidence of approximately 1 in 14,000-18,000 live births2A phase II trial has recently... ► Artikel lesen | |
Sa | H. Lundbeck A/S: New data demonstrates robust efficacy of Vyepti (eptinezumab) in otherwise difficult-to-treat patients with severe migraine | 490 | PR Newswire | The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated statistically significant... ► Artikel lesen | |
Sa | H. Lundbeck A/S: New data from phase III trial confirms efficacy of Vyepti (eptinezumab) in Asian population with chronic migraine | 482 | PR Newswire | The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically significant... ► Artikel lesen | |
10.06. | Investing in China is investing in the future, Lundbeck's senior executive says | 2 | China Daily | ||
29.05. | Lundbeck Foundation: The Brain Prize: HM The King of Denmark presents prestigious prize to US and German scientists for seminal discoveries in brain cancer | 276 | PR Newswire | Two pioneering scientists received The Brain Prize 2025 for their discoveries that open an entirely new way of thinking about and understanding brain cancers, and the potential strategies... ► Artikel lesen | |
22.05. | H. Lundbeck A/S: Lundbeck successfully places a EUR 500 million Eurobond | 786 | GlobeNewswire (Europe) | Valby, Denmark, 22 May 2025 - H. Lundbeck A/S (Lundbeck) has successfully placed an aggregate principal amount of EUR 500 million senior unsecured notes with a tenor of four (4) years maturing 2 June... ► Artikel lesen | |
14.05. | H. Lundbeck A/S: Lundbeck raises financial guidance following strong start to the year with strategic brands growth of +24% CER | 171 | GlobeNewswire (Europe) | Key highlights
Lundbeck's total revenue grew by +16% CER[1] (+18% DKK) to DKK 6,235 million in the first quarter of 2025, with all regions contributing to growth
United States: DKK 3,284 million... ► Artikel lesen | |
08.05. | H. Lundbeck A/S: Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston | 352 | PR Newswire | VALBY, Denmark, May 8, 2025 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) will present key pipeline data and patient perspectives from the phase II AMULET trial, investigating amlenetug as a... ► Artikel lesen | |
06.05. | H. Lundbeck A/S: Lundbeck joins forces with Danish Centre for AI Innovation to improve brain health by advancing drug discovery with Gefion AI supercomputer | 236 | PR Newswire | VALBY, Denmark, May 6, 2025 /PRNewswire/ -- H. Lundbeck A/S is pleased to announce its agreement with the Danish Centre for AI Innovation (DCAI), the company established to run and operate... ► Artikel lesen | |
04.04. | H. Lundbeck A/S: Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting | 505 | PR Newswire | VALBY, Denmark, April 4, 2025 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) will present positive interim results from the open-label extension of the PACIFIC trial investigating bexicaserin... ► Artikel lesen | |
02.04. | Lundbeck shares dop 6% as Deutsche Bank downgrades stock to "hold" | 15 | Investing.com | ||
02.04. | Deutsche Bank cuts Lundbeck stock rating, lowers price target | 49 | Investing.com | ||
01.04. | Lundbeck ends subcutaneous migraine cohort after futility review, pivots to IV formulation | 3 | FierceBiotech | ||
31.03. | H. Lundbeck A/S: Following a planned interim analysis in the PROCEED trial Lundbeck expands the dose finding to intravenous administration of Lu AG09222 in migraine prevention | 303 | PR Newswire | PROCEED is an adaptive Phase IIb trial with Lu AG09222, an investigational mAb intended to block signaling by pituitary adenylate cyclase-activating polypeptide (PACAP), a neuropeptide that... ► Artikel lesen | |
27.03. | Dividendenbekanntmachungen (27.03.2025) | 11.032 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABERDEEN GROUP PLC GB00BF8Q6K64 0,073 GBP 0,0875 EUR AFRICA OIL CORP CA00829Q1019 0,0371 USD 0,0345 EUR AGL ENERGY LIMITED AU000000AGL7 0... ► Artikel lesen | |
26.03. | H. Lundbeck A/S: Lundbeck held its Annual General Meeting on 26 March 2025 at the company's registered office | 511 | PR Newswire | VALBY, Denmark, March 26, 2025 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) announced today that the report by the Board of Directors was adopted and the annual report was approved at the annual... ► Artikel lesen | |
25.03. | Carl Zeiss Meditec, Lundbeck: Dividenden im global market - Ex-Tag 27.03.2025 | 49 | Wiener Börse | ||
14.03. | EC approves Otsuka and Lundbeck's Rxulti for schizophrenia | 4 | Pharmaceutical Technology | ||
13.03. | H. Lundbeck A/S: Rxulti (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older | 531 | PR Newswire | Brexpiprazole's indication for the treatment of schizophrenia in adults is extended to include adolescents aged 13 years and older1Approval follows a positive Committee for Medicinal Products... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BAYER | 26,280 | -0,49 % | Kriegserklärung an Pharmaindustrie!? Bayer, Novo Nordisk und Geheimtipp PanGenomic Health | Hat US-Gesundheitsminister Robert F. Kennedy Jr. der traditionellen Pharmaindustrie den Krieg erklärt? In diese Richtung äußerte sich jedenfalls der ehemalige Trump-Pressesprecher und heutige Podcaster... ► Artikel lesen | |
NOVO NORDISK | 58,34 | +0,78 % | Novo Nordisk inks partnership with WeightWatchers to broaden Wegovy access | ||
PFIZER | 20,720 | -0,02 % | Depot Verdoppler mit Künstlicher Intelligenz: Novo Nordisk, PanGenomic Health und Pfizer zünden 2025 den Profit-Turbo | Lauf BlackRock Health Sciences steht der globale Gesundheitssektor 2025 vor einem beispiellosen Aufschwung. Nach Jahren der Volatilität durch die Pandemie soll die Branche jetzt die höchsten Gewinnzuwächse... ► Artikel lesen | |
NOVARTIS | 103,30 | +0,37 % | Novartis Pharma AG: Novartis completes acquisition of Regulus Therapeutics | Basel, June 25, 2025 - Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. ("Regulus"). With the completion of the acquisition, shares of common... ► Artikel lesen | |
MERCK KGAA | 111,65 | +1,18 % | MilliporeSigma and "Abbott Elementary" Inspire Students' Curiosity With Hands-On STEM | NORTHAMPTON, MA / ACCESS Newswire / June 25, 2025 / Between September 2024 and April 2025, MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, teamed up with... ► Artikel lesen | |
GILEAD SCIENCES | 92,00 | 0,00 % | Assembly Biosciences: ABI-4334 erreicht Studienziel - Gilead-Entscheidung steht bevor | Assembly Biosciences (WKN: A402CB) liefert weiter ab: Mit ABI-4334 fällt der erste wichtige Readout dieses Jahres positiv aus. Das HBV-Asset galt als das unsicherste im Portfolio. Die Aktie liebäugelt... ► Artikel lesen | |
AURORA CANNABIS | 3,685 | +1,38 % | Aurora Cannabis Inc (3): Aurora Cannabis expands compassionate pricing program | ||
SANOFI | 82,97 | +0,27 % | Sanofi und Regeneron erhalten weitere US-Zulassung für Dupixent | DJ Sanofi und Regeneron erhalten weitere US-Zulassung für Dupixent
Von Adria Calatayud
DOW JONES--Sanofi und ihr Partner Regeneron Pharmaceuticals können ihren Entzündungshemmer Dupixent in... ► Artikel lesen | |
GSK | 16,470 | +0,24 % | GSK's Benlysta Autoinjector Gets FDA Approval For Children With Active Lupus Nephritis | LONDON (dpa-AFX) - GSK plc (GSK.L) Tuesday said that the U.S. Food and Drug Administration (FDA) has approved Benlysta autoinjector for individuals aged five years and older with active lupus... ► Artikel lesen | |
ABBVIE | 160,40 | +0,50 % | Aktienmarkt: Kurs der Aktie von AbbVie im Plus (159,9573 €) | Die Aktie von AbbVie notiert heute ein wenig fester. Das Papier kostete zuletzt 185,88 US-Dollar. Der Anteilsschein von AbbVie verzeichnet zur Stunde einen Preisanstieg von 1,15 Prozent. Er hat sich... ► Artikel lesen | |
CANOPY GROWTH | 1,072 | +0,75 % | Canopy Growth Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
ROCHE | 281,90 | +0,57 % | Ihre wichtigsten Termine: Alle Analysten-Augen auf: Kingfisher, Roche, Prosus, New Work und Zooplus! | © Foto: Uwe Anspach/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr... ► Artikel lesen | |
STADA ARZNEIMITTEL | - | - | Stada Health Report: Gesundheitssystem: Bedingt vertrauenswürdig | ||
ELI LILLY | 679,30 | +0,01 % | Blickwechsel Stoffwechsel - erstes Live-Event in NRW von Lilly Deutschland und dem Adipositas Verband e. V. bringt zentrale Akteure an einen Tisch | Düsseldorf (ots) - Gemeinsam stark gegen Adipositas - Nordrhein-Westfalens Zukunftsplan für Prävention und VersorgungIn Deutschland lebt rund ein Viertel der Erwachsenen mit Adipositas (BMI >=30 kg/m²).[1]... ► Artikel lesen | |
MERCK & CO | 67,90 | +0,74 % | Merck & Co.: Patente, Prognosen und eine fatale Fehleinschätzung | Auslaufende Patente, geopolitische Risiken, Abschreibungen. Merck steht unter Druck, doch abseits der Schlagzeilen läuft das Geschäft erstaunlich gut Den vollständigen Artikel lesen ... ► Artikel lesen |